WALD WALDENCAST ACQUISITION CORP

Waldencast Announces Participation in Upcoming Investor Conferences

Waldencast Announces Participation in Upcoming Investor Conferences

WHITE PLAINS, N.Y., May 30, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the Company will participate in upcoming investor conferences.

On June 5, 2024, the Company will participate in the TD Cowen 8th Annual Future of the Consumer Conference being held at the Conrad New York Downtown in New York City. Management will host a fireside chat presentation at 1:00 p.m. Eastern Time and hold investor meetings throughout the day.

On June 10, 2024, the Company will participate in the Oppenheimer 24th Annual Consumer Growth and E-Commerce Conference being held virtually. Management will host a fireside chat presentation at 9:45 a.m. Eastern Time and host virtual meetings throughout the day.

The fireside chat presentations at both conferences will be available live and for replay on the Investor Relations page on the company's website at

About Waldencast

Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Skincare and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: . 

Contacts

Investors

ICR

Allison Malkin

Media

ICR

Brittney Fraser/Alecia Pulman



EN
30/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WALDENCAST ACQUISITION CORP

 PRESS RELEASE

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable ...

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® MagIQ™ injectable hyaluronic acid (“HA”) gel, the first product ...

 PRESS RELEASE

Waldencast Announces Strong Progress on Business Priorities for H1 202...

Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand’s Addressable Market in the U.S. Milk Makeup Delivers Strong Retail Sales Performance in U.S. Retail in H1 2025 and Expands Its Digital Footprint in Q2 Company Launches an Exploration of Strategic Alternatives to Enhance Shareholder Value Company Postpones H1 2025 Earnings Release and Conference Call; Provides Update to FY 2025 Guidance LONDON, Aug...

 PRESS RELEASE

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injecta...

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthe...

 PRESS RELEASE

Waldencast Reports Q1 2025 Financial Results

Waldencast Reports Q1 2025 Financial Results Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended March 31, 2025 (“Q1 2025”) on Form 6-K to the U.S. Securities and Exchange Commission (the “SEC”), which are also available on our investor relations site at /. Michel Brousset, W...

 PRESS RELEASE

Waldencast plc Announces First Quarter Fiscal 2025 Results Conference ...

Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast LONDON, May 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its First Quarter Fiscal 2025 conference call and webcast. As previously announced, the Company will issue its First Quarter Fiscal 2025 results on May 13, 2025 after the close of the U.S. market. Management will host a conference call to discuss its First Quarter Fiscal 2025 results on May 14, 2025 at 8:30am ET. Investors and analysts in...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch